home / stock / lly / lly articles

LLY Articles, Eli Lilly and Company - From 06/21/24

Stock Information
Company Name: Eli Lilly and Company
Stock Symbol: LLY
Market: NYSE
Website: lilly.com
Menu
LLY LLY Quote LLY Short LLY News LLY Articles LLY Message Board
Get LLY Alerts

News, Short Squeeze, Breakout and More Instantly...
Nestle Carefully Targets Weight-Loss Drug Users with New Food Line | Benzinga

Last month, Nestlé SA (OTC:NSRGF) (OTC:NSRGY) unveiled Vital Pursuit, a new line of foods designed to complement GLP-1 weight loss ...
German Drug Developer Evotec Seeks Adviser Input As Takeover Concerns Mount | Benzinga

German drug developer Evotec SE (NASDAQ:EVO) is reportedly consulting defense advisers following a significant drop in share price, raising concern...

Eli Lilly Expands Fight Against Counterfeit Obesity Drug Zepbound With New Legal Actions | Benzinga

Eli Lilly & Co. (NYSE:LLY) has intensified its fight against counterfeit versions of its popular obesity drug, Zepbound, by initiating addition...

Here's How Much $1000 Invested In Eli Lilly and Co 10 Years Ago Would Be Worth Today | Benzinga

Eli Lilly and Co (NYSE:LLY) has outperformed the market over the past 10 years by 19.61% on an annualized basis producing an average annual return ...
BioRestorative Therapies Enters Preclinical Assessment Of Its Patented Stem-Cell Technology Prior To First-In-Human Studies | Benzinga

Clinical-stage biotech innovator BioRestorative Therapies (NASDAQ:BRTX) recently announced that it is entering a new program of preclinical metabol...

What's Going On With Small-Cap Cancer Focused Nurix Therapeutics On Monday? | Benzinga

Sunday, Nurix Therapeutics Inc (NASDAQ:NRIX) announced the presentation of updated clinical data for NX-5948, an orally bioavailable degrader of Br...

Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails | Benzinga

This week, an FDA advisory committee unanimously recommended approval of Eli Lilly's (NYSE: LLY) Alzheimer's disease drug, donanemab. Pfize...
JPMorgan's $500M Venture Capital Fund Bets Big On Weight-Loss Drugs: 'They're All The Rage' | Benzinga

JPMorgan Chase & Co.’s (NYSE:JPM) asset management division has reportedly secured over $500 million for a biotech venture capital fund f...

Jim Cramer Sees Eli Lilly As More Than A 'One-Trick Pony' After FDA Advisors Back Its Alzheimer's Drug: 'It's Ultimately Headed To A Trillion Dollar Valuation' | Benzinga

Jim Cramer has expressed his confidence in Eli Lilly and Co (NYSE:LLY), citing the company’s diverse drug portfolio and the recent endorsemen...

Eli Lilly's Donanemab Gains Favorable FDA Advisory Verdict, Boosting Stock Potential, Says BofA Analyst | Benzinga

BofA Securities analyst Geoff Meacham reiterated the Buy rating on Eli Lilly And Company (NYSE:LLY), with a price forecast of $1,000. An advisory c...
Previous 10 Next 10